Dr. Jeff Hersh| Daily News Correspondent

Q: What is CAR T-cell therapy?

A: Our immune system protects our bodies from "invasion"by harmful substances, infections and abnormal cells (for example cancer cells). T-cells (also called T-lymphocytes or thymocytes) develop from stem cells in the bone marrow and mature in the thymus (a body organ in the neck that is part of the lymphoid system, along with the spleen, lymph nodes and the red bone marrow).

Cytotoxic T-cells identify body cells that have certain antigens (proteins on the surface of certain cancer cells, cells that have become infected, other cells) and directly kill them.

Helper T-cells detect various "invasions"and release cytokines to activate other immune system cells (including cytotoxic T-cells) to combat them.

Regulatory T-cells help moderate the immune response to maintain balance and the bodys ability to tolerate (rather than attack) itself (for example helping minimize inappropriate inflammatory responses).

This description of T-cells shows why it would be helpful to "manipulate"them in a specific manner to leverage the immune system to help fight certain diseases/conditions. This is where chimeric antigen receptor (CAR) T-cells come into play.

White blood cells (including T-cells) are collected from the patient by taking some of their blood via an intravenous (IV) catheter and filtering out the white cells using a leukapheresis machine, and then putting the filtered blood (minus the extracted white blood cells) back into the patient via a second IV catheter.

The T-cells are then separated from the other white blood cells, and a gene for the "targeted" antigen is added to the cells (you can think of this as a "lock and key"mechanism, with the antigen being the "lock"and the protein added to the T-cell being the "key"used to identify the "invading" cell with that particular antigen "lock."

These modified cells (the CAR T-cells) are then "multiplied"in the lab to create a large number of them. The CAR T-cells are then infused into the patient (again via an IV). These CAR T-cells can now specifically "hunt"the specific "invading"cell(s) they have been created to target.

There are many steps needed to create this personalized CAR T-cell treatment for an individual patient, and therefore it can take weeks to produce these treatments. In the future it may be possible to pre-prepare treatments from donor T-cells (possibly modifying these cells to target specific antigens using techniques like CRISPR, mRNA techniques, etc.) and then transfuse the appropriate CAR T-cells in a manner similar to how other blood products (for example red cells, platelets, etc.) are transfused to help a patient.

Since 2017 CAR T-cells have been specifically designed and utilized to treat individual patients with several different types of "blood cancers"(lymphomas, leukemias and multiple myelomas) that did not respond to the standard treatments (for example chemotherapy for that type of cancer).In many patients with very difficult to treat blood cancers, these treatments have been very effective.

Solid tumors (as opposed to blood cancers), such as brain, breast, lung and pancreatic cancers, are a bit more challenging to address with the CAR T-cell approach.This is because having the CAR T-cells gain "access"to the solid tumor cancer cells is more difficult.

From the description of T-cells above, it seems that this same conceptual approach might be utilized to treat certain autoimmune conditions (conditions where a patients own immune system "overreacts"and attacks the patients own body cells), and this has recently been studied. In this study, five patients with severe lupus who had not responded to standard treatments were treated with specifically designed CAR T-cells to "wipe out"the aberrant B cells causing their autoimmune complications, and all five showed very significant improvement. Future clinical studies will no doubt be designed to see what other conditions might benefit from this treatment approach!

However, treatment with CAR T-cells is not without risk, as these treatments can sometimes cause serious and even life-threatening complications. For example, some patients have had:

Cytokine release syndrome (CRS), where the patient reacts to the CAR T-cell infusion with an aggressive release of cytokines that causes an inflammatory reaction (for example causing symptoms like fever, breathing issues, gastrointestinal issues, other symptoms); nervous system issues (for example headaches, seizures, alterations in consciousness, others), and there may bemany other possible complications.

Bottom line: CAR T-cell therapy has become a more and more accepted therapeutic approach, and in the future it may be utilized earlier in a patients disease (rather than only for refractory cases), and for a broader array of disease states (not just blood cancers, but potentially autoimmune conditions, maybe certain solid tumors, and potentially other diseases).

Jeff Hersh, Ph.D., M.D., can be reached at DrHersh@juno.com.

Read the original:
CAR T-cell therapy is new approach to fighting cancer, other diseases - MetroWest Daily News

Bone Marrow Stem Cells Comments Off on CAR T-cell therapy is new approach to fighting cancer, other diseases – MetroWest Daily News | October 5th, 2022

Pain.

It gnawsat you. It drains you. It becomes the focus of your life.

Experiencing a few pain-free moments can be euphoric; it makes you realize how long youve been living with aches and pain. You might wonder how you can find a solution to relieve the pain and regain your freedom from discomfort.

Regenerative Spine and Pain Institute on how to lesson your pain.

Dr. Ronak Patel at Regenerative Spine and Pain Institute wants you to know there are two new revolutionary answers to pain relief.

Both platelet-rich therapy otherwise known as PRP and stem cell therapy give patients new hope by using the bodys powerful healing power to accelerate the battle against pain. Dr. Patel has seen incredible success implementing these cutting-edge treatments on hundreds of patients suffering from pain-related issues.

So if you are suffering fromany of the ailments below, theres a lifeline.

Heres the best news: Neither PRP or stem cell therapy involves drug use with side effects or any surgical procedures.

Both PRP and stem cell treatments use the bodys own healing resources to repair diseased or damaged tissue and the results are quite remarkable.

PRP therapy involves injecting concentrated platelets and growth factors into damaged tissue to stimulate the faster growth of new healthy cells. Platelets are cells that prevent and stop bleeding. If a blood vessel is damaged, the body sends signals to our platelets to get on the job and start the healing. Some call platelets the bodys natural bandage.

So how does PRP therapy work? Its basically drawing a one small vial of blood from the patient and then using a centrifuge to turn it into a potent and concentrated form of platelets. It is then injected back into the patient. Think of it as a boost of your own blood only superpowered.

Recovery time for PRP therapy is far shorter than for surgery. Patients usually experience soreness for a week or so, but the gradual improvement soon begins. Unlike a steroid shot, which gives you immediate relief and quickly wears off, a PRP patient will see pain symptoms improve over a period of months, and up to 80 percent of patients will see relief for up to two years.

Stem cell therapy can be an even more powerful way to harness the bodys healing power. Stem cells are the building blocks for every cell in our body. These powerful cells can be harvested to produce powerful new cells to fight inflammation and disease.

For those suffering from osteoarthritis, stem cell therapy has proven very effective. Thats because the stem cells may help develop new cartilage cells and suppress inflammation. Stem cells can be harvested through a sample of body fat or bone marrow or be harvested from donated umbilical cord tissue.

And yes, you can even augment PRP therapy with stem cell therapy for an even bigger boost!

Stop wondering if youll have to live with your pain forever. Contact Regenerative Spine and Pain Institute today at 609-269-4451 or go to http://www.njpaindoc.com to book an appointment and learn more.

Go here to see the original:
Regenerative Spine and Pain Institute: Treating Pain with PRP and Stem Cell Therapy - Community News

Bone Marrow Stem Cells Comments Off on Regenerative Spine and Pain Institute: Treating Pain with PRP and Stem Cell Therapy – Community News | October 5th, 2022

NEW YORK, Oct. 4, 2022 /PRNewswire/ --

Growing Use of IVF and Stem Cell Therapies to Create US$ 323 Million Market Opportunity for Carbon Dioxide Incubator Manufacturers

The carbon dioxide incubators market is well covered by Fact.MR for the upcoming decade. The study looks closely at key growth factors such trends, future projections, and business strategies. The research also provides a thorough analysis of the top segments including product, application, capacity, and region, in order to provide well-rounded perspective.

Fact.MR Logo

Fact.MR A Market Research and Competitive Intelligence Provider: The global carbon dioxide incubators market is likely to reach US$ 483.5 Million by 2027, growing at 8.4% CAGR between 2022 and 2027. Growing investment in research and clinical trial activities is likely to fuel the sales of carbon dioxide incubators during the assessment period. Further, use of carbon dioxide incubators in IVF and stem cell treatments is also likely to drive growth.

The popularity and acceptance of in-vitro fertilizations has grown significantly. According toNational Library of Medicine, around 10% to 15% couples in the U.S. have trouble in having a baby. These challenges have been well-addressed by in vitro fertilization (IVF), owing to which it has become a popular healthcare solution.

Use of in-vitro fertilization (IVF) to help couples in becoming parents is likely to grow in the future, which is likely to drive demand for accessories and equipment used in this process. Owing to this, demand for carbon dioxide incubators is likely to witness an upward trend over the upcoming decade.

Further, sales of carbon dioxide incubators are also likely to increase on account of growth in overall stem cell procedures. For instance, as perHealth Resources and Services Administration, 4,864 unrelated and 4,160 related bone marrow and cold transplants were conducted in the U.S. in 2020. Growing use of stem cell treatment is likely to be a key factor driving the sales of carbon dioxide incubators during the assessment period.

Story continues

For Critical Insights on this Market, Request for More Info at:

https://www.factmr.com/connectus/sample?flag=S&rep_id=7717

Globally, North America and Europe are likely to remain at the pinnacle of growth in the carbon dioxide incubators market. The U.S., U.K., France, and Germany are at the forefront of new innovation in R&D, and sales of medical accessories and equipment will also remain high, as per Fact.MR. Owing to these factors, carbon dioxide incubator manufacturers are likely to witness incremental growth opportunities across these regions.

Key Takeaways:

By product, water-jacketed carbon dioxide incubators are likely to reman preferred among end-users.

By capacity, below 100-liter carbon dioxide incubators are expected to witness high demand during the assessment period.

By application, use of carbon dioxide incubators in laboratory research and clinical applications is likely to remain high during the assessment period.

By region, North America and Europe are likely to hold sway over the forecast period, with the U.S. and the U.K. leading the growth.

China and India are expected to create sizeable opportunities for market players on the back of improved healthcare infrastructure.

Growth Drivers:

Increasing applications of carbon dioxide incubators in in-vitro fertilization (IVF) and stem cell treatment is likely to drive the market.

Use of carbon dioxide incubators in cell culture development and tissue engineering is expected to create growth avenues for market players.

Efficiency of incubators in maintaining consistent temperature during genetically modified organism (GMO) cultivation is expected to drive growth.

Advancement in carbon dioxide incubator technology is likely to create new growth avenues for market players.

Restraints:

Carbon dioxide incubators are highly prone to errors due to which they require highly experienced technicians. Due to skill shortage, sales of these incubators can be limited.

Lack of standardization is a longstanding challenge and failure to address this issue might hamper growth.

Get Customization on this Report for Specific Research Solutions

https://www.factmr.com/connectus/sample?flag=RC&rep_id=7717

Competitive Landscape:

Carbon dioxide incubator manufacturers are focusing on launching innovative technologies to consolidate their position in the market. Further, leading players are concentrating on providing training and guidelines to end-users so their products can be used without any issue.

For instance,

In May 2021, Esco introduced an innovative incubator featuring High Heat Sterilization that is highly effective in eliminating bacteria and vegetative cells.

In January 2020, CO2Meter Inc., launched incubators that regulate and monitor bacterial development patterns.

Key Companies Profiled by Fact.MR

More Valuable Insights on Carbon Dioxide Incubators Market

In its latest study, Fact.MR offers a detailed analysis of the global carbon dioxide incubators market for the forecast period of 2022 to 2027. This study also divulges key drivers and trends promoting the sales of carbon dioxide incubators through detailed segmentation as follows:

By Product:

Water Jacketed

Air Jacketed

Direct Heat

By Capacity:

Below 100 Litres

100-200 Litres

Above 200 Litres

By Application:

By Region:

North America

Latin America

Europe

East Asia

South Asia & Oceania

MEA

Interested to Procure The Data? Inquire here

https://www.factmr.com/connectus/sample?flag=EB&rep_id=7717

Key Questions Covered in the Carbon Dioxide Incubators Market Report

What is the estimated market size of carbon dioxide incubators in 2022?

At what pace will worldwide carbon dioxide incubators sales increase till 2027?

What factors are driving demand in the carbon dioxide incubators market?

Which region is predicted to lead the worldwide carbon dioxide incubators market between 2022 and 2027?

What are the elements driving carbon dioxide incubators market sales during the forecast period?

What is the expected market estimation of the carbon dioxide incubators market during the forecast period?

Explore Fact.MR's Coverage on the Healthcare Domain

Biological Indicator Incubator Market:The biological indicator incubators market is projected to benefit from rising biopharmaceutical production. The market for biological indicator incubators may continue to increase quickly as a result of the manufacturing of biopharmaceuticals that are grown via cell culture.

Tissue Culture Incubator Market:The introduction of CO2 incubators with infrared radiation control systems and other technological advancements in tissue culture incubators, along with increased funding for tissue-based research, are anticipated to be major factors driving the growth of the tissue culture incubator market over the forecast period.

Pneumatic Nebulizers Market:Pneumatic nebulizer sales are anticipated to grow steadily at a CAGR of 4% and reach a market value of US$ 850.4 million by 2027 from US$ 699 million in 2022. An increase in local healthcare spending and patient awareness has spurred the need for pneumatic nebulizers.

Implantable Medical Devices Market: The global implantable medical devices market is predicted to reach US$ 155 billion by 2027. Key factors driving market growth include rising geriatric population & burden of chronic diseases and increasing demand for cosmetic dentistry.

Disinfection Caps Market: Key factors driving market growth include stringent regulations for safe injection practices and rising prevalence of hospital-acquired infections across the world. The global disinfection caps market is estimated to reach US$ 420 million by 2027.

Check it Out More Reports by Fact.MR on Healthcare Domain

https://www.factmr.com/industry/healthcare

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories. We are committed to deliver insights that help businesses gain deeper understanding of their target markets. We understand that making sense of the vast labyrinth of data can be overwhelming for businesses. That's why focus on offering insights that can actually make a difference to bottom-lines.

Specialties:Competition Tracking, Customized Research, Syndicated Research, Investment Research, Social Media Research, Business Intelligence, Industry Analysis, Thought Leadership.

Contact: Mahendra SinghUS Sales Office11140Rockville PikeSuite 400Rockville, MD20852United StatesTel: +1 (628) 251-1583, +353-1-4434-232E:sales@factmr.com

Follow Us:LinkedIn | Twitter| Blog

Cision

View original content:https://www.prnewswire.com/news-releases/carbon-dioxide-incubators-market-to-reach-us-483-5-million-by-2027-as-application-in-in-vitro-fertilization-rises-301640474.html

SOURCE Fact.MR

Link:
Carbon Dioxide Incubators Market to Reach US$ 483.5 Million by 2027 as Application in In Vitro Fertilization Rises - Yahoo Finance

Bone Marrow Stem Cells Comments Off on Carbon Dioxide Incubators Market to Reach US$ 483.5 Million by 2027 as Application in In Vitro Fertilization Rises – Yahoo Finance | October 5th, 2022

LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today the agenda for its virtual Capital Markets Day on 12 October 2022 at 8:00 am ET (1 pm UK).

Go here to see the original:
COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022

Global News Feed Comments Off on COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022 | October 5th, 2022

POTOMAC, Md., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Castellum, Inc. (“Castellum”) (OTC: ONOV), a cybersecurity, electronic warfare, and IT services company, announced today that, subject to meeting all requirements (including the price requirement) at the time of listing, the Company’s application to list its shares of common stock (the “Common Stock”), has been approved to uplist to the NYSE American Exchange in conjunction with an underwritten public offering and a one-for-twenty reverse stock split of the Common Stock effective on or about October 7, 2022. The ticker symbol for the Common Stock will change to “CTM” upon listing. Trading of the Common Stock is expected to commence on or about October 7, 2022. The new CUSIP for the Common Stock following the reverse stock split will be 14838T204.

Read the rest here:
Castellum, Inc. Announces Intent to Uplist to NYSE American Exchange

Global News Feed Comments Off on Castellum, Inc. Announces Intent to Uplist to NYSE American Exchange | October 5th, 2022

Robust recruitment activities experienced in closing weeks of September44 patients now enrolled

Read the original:
Spectral Medical Provides Update on Tigris Clinical Trial

Global News Feed Comments Off on Spectral Medical Provides Update on Tigris Clinical Trial | October 5th, 2022

Walnut Creek, CA; Boston, MA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group ("DHC"), the leading global consultancy to the cell and gene therapy (“CGT”) industry, and WestView Capital Partners (“WestView”), a Boston-based growth equity firm, are pleased to jointly announce that WestView has completed a growth investment in DHC.

See the rest here:
Correction: Dark Horse Consulting Group Welcomes Growth Investment from WestView Capital Partners

Global News Feed Comments Off on Correction: Dark Horse Consulting Group Welcomes Growth Investment from WestView Capital Partners | October 5th, 2022

Chief Visionary Officer of Psycheceutical, Zappy Zapolin, will join other prominent leaders in Psychedelics on Benzinga’s Council Board Chief Visionary Officer of Psycheceutical, Zappy Zapolin, will join other prominent leaders in Psychedelics on Benzinga’s Council Board

Visit link:
Psycheceutical Bioscience, Inc.'s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council

Global News Feed Comments Off on Psycheceutical Bioscience, Inc.’s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council | October 5th, 2022

ZURICH, Switzerland, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date.

Read the original here:
Araris Biotech Closes $24 Million Financing Round

Global News Feed Comments Off on Araris Biotech Closes $24 Million Financing Round | October 5th, 2022

Industry veteran brings nearly 20 years of broad leadership experience in biopharma Industry veteran brings nearly 20 years of broad leadership experience in biopharma

The rest is here:
BlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer

Global News Feed Comments Off on BlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer | October 5th, 2022

Company announcement no. 16 - 224 October 2022

Original post:
Transactions in connection with share buy-back program

Global News Feed Comments Off on Transactions in connection with share buy-back program | October 5th, 2022

Company announcement – No. 43 / 2022

Follow this link:
Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares

Global News Feed Comments Off on Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares | October 5th, 2022

Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2022.

Go here to read the rest:
Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2022

Global News Feed Comments Off on Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2022 | October 5th, 2022

LOS ANGELES, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the 147th Annual Meeting of the American Neurological Association (ANA). Dr. Peter M. Clark, of the University of California Los Angeles, will present preclinical research highlighting the use of Trethera’s deoxycytidine kinase (dCK) inhibitor, TRE-515, to selectively inhibit symptoms in experimental autoimmune encephalomyelitis (EAE) mouse models of multiple sclerosis (MS). The ANA meeting is one of the largest annual gatherings of MS researchers and a key venue for presenting noteworthy neurology discoveries. The work presented by Dr. Clark also has application for optic neuritis, a rare neurologic disease which affects the optic nerve causing visual impairment. TRE-515 is currently being evaluated in a Phase 1 dose escalation solid tumors study.

Visit link:
Trethera Announces Multiple Sclerosis Treatment Poster Presentation at the American Neurological Association Annual Meeting

Global News Feed Comments Off on Trethera Announces Multiple Sclerosis Treatment Poster Presentation at the American Neurological Association Annual Meeting | October 5th, 2022

Saint Herblain (France), October 4, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (the “Company”), a specialty vaccine company, announced today the closing of its previously announced global offering to specified categories of investors of an aggregate 21,000,000 new ordinary shares, consisting of a public offering of 375,000 American Depositary Shares (“ADSs”), each representing two ordinary shares, in the United States at an offering price of $9.51 per ADS (the “U.S. Offering”), and a concurrent private placement of 20,250,000 ordinary shares in Europe (including France) and other countries outside of the United States at the corresponding offering price of €4.90 per ordinary share (the “European Private Placement”, and, together with the U.S. Offering, the “Global Offering”). Aggregate gross proceeds of the Global Offering, before deducting underwriting commissions and estimated expenses payable by the Company, were approximately €102.9 million ($99.9 million).

More here:
Valneva Announces Closing of Upsized €102.9 Million Global Offering

Global News Feed Comments Off on Valneva Announces Closing of Upsized €102.9 Million Global Offering | October 5th, 2022

- IVX-A12 is the first combination bivalent vaccine candidate against both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) to reach clinical stage -

Go here to see the original:
Icosavax Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults

Global News Feed Comments Off on Icosavax Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults | October 5th, 2022

BELTSVILLE, Md., Oct. 04, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1b/2 clinical trial to evaluate NC410 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with immune checkpoint refractory or immune checkpoint naïve solid tumors. In addition, NextCure announced it has entered into a supply agreement for KEYTRUDA with Merck (known as MSD outside the United States and Canada).

See the original post here:
NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune...

Global News Feed Comments Off on NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune… | October 5th, 2022

CAMBRIDGE, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on October 3, 2022, an authorized sub-committee of the Compensation Committee of the Board of Directors of Mersana granted inducement awards, consisting of restricted stock unit awards (RSUs) to acquire an aggregate of 27,000 shares of its common stock, to six new employees whose employment commenced in September 2022. The awards were granted pursuant to terms and conditions fixed by the Compensation Committee and as an inducement material to each new employee entering employment with Mersana in accordance with Nasdaq Listing Rule 5635(c)(4).

More:
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Global News Feed Comments Off on Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | October 5th, 2022

NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dante Genomics, a global leader in genomics and precision medicine, is pleased to announce that the Company’s co-founder and CEO Andrea Riposati presented as an opening speaker on Tuesday, September 27, 2022 at the 77th United Nations General Assembly (UNGA) Science Summit, where he unveiled the Company’s Digital Health Population Genomics Program in Europe, including living labs, which are groundbreaking pilot studies with fast impact on a country’s society and digital health.

Continue reading here:
Dante Genomics Unveils Digital Health Population Genomic Programs at the United Nations General Assembly Science Summit

Global News Feed Comments Off on Dante Genomics Unveils Digital Health Population Genomic Programs at the United Nations General Assembly Science Summit | October 5th, 2022

Company announcement – No. 44 / 2022

See more here:
Zealand Pharma announces completion of a directed issue and private placement of 4,975,000 new ordinary shares raising gross proceeds of approx. DKK...

Global News Feed Comments Off on Zealand Pharma announces completion of a directed issue and private placement of 4,975,000 new ordinary shares raising gross proceeds of approx. DKK… | October 5th, 2022